5nance5nance
5nance5nance
HomeScreens
LOGINGET FREE ACCOUNT

Caplin Point Laboratories Ltd.

•
caplinpoint.netBSE: 524742NSE: CAPLIPOINT
Market Cap₹ 20,939 Cr.
Current Price
High / Low₹ 2,877 / 1,500
Stock P/E49.9
Book Value₹ 283
Price to Book5.63
Dividend Yield0.29 %
ROCE27.1 %
ROE21.4 %
Face Value₹ 2

Add ratio to table

ABOUT

AI Sector View

AI GENERATED

Healthcare

Buy

This stance relies on proxies and positioning because no direct pharma-export or healthcare operating series exists in the dataset. The depreciated currency at 95.23 (Sep/26) can support export earnings, inflation at 4.45% (Jul/26) is manageable for a defensive sector, and consumer spending remains large at INR 44743 billion (Jun/26). Strong FPI inflow of INR 10620 crore over 3 months to 2026-08-31 from INR -11381 crore in the prior 3 months adds a real sector-specific tailwind, but confidence stays capped because the fundamental drivers are indirect proxies.

Confidence
50%
View full sector analysis →

PROS

  • Company has delivered good profit growth of 20.5% CAGR over last 5 years
  • Company is almost debt free
  • Company has a healthy return on capital (ROCE) of 28.2%
  • Company has a good return on equity (ROE) track record: 3 Years ROE 22.1%
  • Latest quarter profit grew 40.2% YoY, showing strong momentum

CONS

  • Receivables are growing faster than sales - a possible quality concern
  • A large part of profit comes from other income (38.5% of PBT)
  • Poor cash conversion - profits are not backed by operating cash flow (CFO/PAT 0.50x)
  • Operating margins have contracted to 45.7% from 60.3%
  • Stock is trading at 5.6x its book value

* The pros and cons are machine generated based on quantitative rules.

Peer comparison

HealthcareHealthcarePharmaceuticals & Drugs
Part ofNIFTY TOTAL MKTNIFTY 500NIFTY SMLCAP 250NIFTY MULTI MQ 50
S.No.Name
1.SUNPHARMA1842.0036.54441957.500.872901.2326.5315299.8810.9819.1128.81
2.DIVISLAB9326.0084.64247576.000.32902.0065.503080.0027.8021.5140.75
3.TORNTPHARM4975.0086.76189233.010.76566.003.284921.0057.3219.2733.81
4.ZYDUSLIFE1119.5024.74111670.550.09990.20-34.908017.0023.9721.3924.54
5.CIPLA1365.0032.72110272.680.95785.55-39.187119.284.1316.0016.73
6.LAURUSLABS1970.3597.37106460.420.10362.07123.942026.3129.1018.2031.50
7.DRREDDY1161.0030.0796906.380.69435.60-69.108099.80-5.2113.7510.63
8.AUROPHARMA1675.4525.9796401.690.241032.0325.229150.3517.4412.7620.54
9.LUPIN2096.0017.3495842.920.861416.9816.018276.8934.2828.8629.59
10.MANKIND2277.0046.0494050.370.04574.0929.124030.5912.8913.2426.30
11.GLENMARK2416.9037.9468210.880.10482.83927.884018.4831.3520.3520.03
12.CAPLIPOINT2754.7531.4720939.320.29179.0918.79610.3619.6324.9734.97
Detailed Comparison with:

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
174179133139186208185174183175189191203
9790708210411010899969998108115
Operating Profit77896358819877758776928488
OPM %44.12%49.91%47.67%41.38%43.84%47.21%41.78%43.22%47.44%43.30%48.47%43.68%43.26%
27241836224329413259326163
Interest0000000000000
Depreciation7777666666677
Profit before Tax97107748797135100110112129117138151
Tax %21.52%23.41%25.50%19.59%24.97%21.48%25.42%21.48%23.63%20.47%25.41%20.49%20.06%
Net Profit768255707310675868610387110120
10.0410.827.309.209.5513.929.8311.3711.3013.5011.4915.8915.84

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
342427537528483528529625752738759
248285348321273309309338420401420
Operating Profit94142189207210219219287332338339
OPM %27.47%33.28%35.13%39.22%43.41%41.56%41.50%45.93%44.12%45.75%44.68%
132435662357100106135195215
Interest11100000000
Depreciation1319212022262627252526
Profit before Tax93146203253210250293366442508534
Tax %24.05%29.95%26.89%21.92%25.58%24.95%20.09%22.43%23.13%21.86%21.44%
Net Profit70102148198156188234284339397420
EPS9.3013.5719.5025.9520.4524.6030.6237.3544.6752.18—
Dividend Payout %16.12%14.78%11.23%9.57%14.53%16.14%14.58%13.39%13.43%15.33%—

COMPOUNDED SALES GROWTH

10 Years:
12%
5 Years:
9%
3 Years:
12%

COMPOUNDED PROFIT GROWTH

10 Years:
24%
5 Years:
20%
3 Years:
19%

STOCK PRICE CAGR

10 Years:
27%
5 Years:
24%
3 Years:
42%
1 Year:
23%

RETURN ON EQUITY

10 Years:
30%
5 Years:
22%
3 Years:
22%
Last Year:
21%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Corporate actions

2026

Sep 18

₹ 2

Rs.4.0000 per share(200%)Final Dividend

2026

May 29

₹ 2

Rs.4.0000 per share(200%)Interim Dividend

2025

Sep 12

₹ 1.50

Rs.3.0000 per share(150%)Final Dividend

2025

May 30

₹ 1.50

Rs.3.0000 per share(150%)Interim Dividend

2024

Sep 23

₹ 1.25

Rs.2.5000 per share(125%)Final Dividend

2024

May 31

₹ 1.25

Rs.2.5000 per share(125%)Interim Dividend

2023

Sep 14

₹ 1.25

Rs.2.5000 per share(125%)Final Dividend

2023

Jun 9

₹ 1

Rs.2.0000 per share(100%)Interim Dividend

2022

Sep 21

₹ 1

Rs.2.0000 per share(100%)Final Dividend

2022

May 23

₹ 1

Rs.2.0000 per share(100%)Interim Dividend

2021

Sep 20

₹ 0.75

Rs.1.5000 per share(75%)Final Dividend

2021

May 18

₹ 0.75

Rs.1.5000 per share(75%)Interim Dividend

2018

Sep 18

₹ 1

Rs.2.0000 per share(100%)Dividend

2017

Sep 7

₹ 0.75

Rs.1.5000 per share(75%)Dividend

2016

Sep 1

₹ 0.35

Rs.3.5000 per share(35%)Final Dividend

2016

Feb 15

₹ 0.25

Interim Dividend

2015

Oct 29

₹ 0.50

Rs.5.0000 per share(50%)Dividend

2020

Jun 18

₹ 0.20

Rs.0.4000 per share(20%)Final Dividend

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital15151515151515151515
1852774105757299001,1091,3611,6662,017
1625432344
Trade Payables66736051706571796193
504052444371106656982
Total Liabilities3174115396918611,0541,3031,5221,8142,212
152169138167183162157166205223
Capital Work in Progress31594124328219
19481681961492654855848021,047
22282422254352866686
0000000129175266
Cash & Bank77284558345316271216215206
44121156244157266296314330374
Total Assets3174115396918611,0541,3031,5221,8142,212

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
7657148137350293222111196203
Cash from Investing-37-60-77-41-4-276-87-119-140-213
Cash from Financing-7-12-15-33-3-23-30-34-38-46
12-491613287-6840-4218-56

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026

Shareholding Pattern

Numbers in percentages

Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
70.5670.5670.5670.5670.5670.5770.5770.5770.57
3.373.714.865.736.176.486.556.155.75
1.491.832.112.002.222.102.052.142.49
Government0.000.000.000.000.000.000.000.000.00
24.5723.9122.4721.7021.0520.8220.7921.1421.18

Documents

Corporate disclosures, annual reports, credit ratings, and concall transcripts

2026-09-04
Copy of Newspaper Publication

2026-09-04 - Caplin Point Laboratories Limited has informed the Exchange about Copy of Newspaper Publication

2026-09-04
Updates

2026-09-04 - Caplin Point Laboratories Limited has informed the Exchange regarding 'Letter to Shareholders'.

2026-09-03
Updates

2026-09-03 - Caplin Point Laboratories Limited has informed the Exchange regarding 'Business Responsibility and Sustainability Reporting (BRSR)'.

2026-09-03
Shareholders meeting

2026-09-03 - Caplin Point Laboratories Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on September 25, 2026

2026-09-02
Spurt in Volume

2026-09-02 - Significant increase in volume has been observed in Caplin Point Laboratories Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, had written to the company. Caplin Point Laboratories Limited has submitted their response.

2026-09-02
Copy of Newspaper Publication

2026-09-02 - Caplin Point Laboratories Limited has informed the Exchange about Copy of Newspaper Publication

2026-09-01
Updates

2026-09-01 - Caplin Point Laboratories Limited has informed the Exchange regarding 'Receipt of Good Manufacturing Practices (GMP) Compliance Certification by Caplin One Labs Limited (COL), a subsidiary company, from INVIMA'.

2026-09-01
Spurt in Volume

2026-09-01 - Significant increase in volume has been observed in Caplin Point Laboratories Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, has written to the company. The response from the company is awaited.

2026-08-21
Updates

2026-08-21 - Caplin Point Laboratories Limited has informed the Exchange regarding 'Completion of Unannounced US FDA Inspection at the facility of Caplin Steriles Limited (Company s Subsidiary)'.

News

Recent coverage and analyst commentary for CAPLIPOINT

Loading news…

🤖

AI Stock Analyst

Caplin Point Laboratories Ltd.

🔒

Sign in to Chat with AI

Log in with your 5nance account to ask institutional questions about performance, financials, and outlook.

✨ Sign In to Chat

Free 5nance Account

5nance5nance

Stock analysis and screening tool

5nanceAI © 2020-2026

Made with ❤️ in India.

Data provided by Accord Fintech

Terms & Privacy.

Product

PremiumWhat's new?Learn

Team

About usSupport

Theme

5nance5nance

Product

PremiumWhat's new?Learn

Team

About usSupport

Theme

5nanceAI © 2020-2026

Data provided by Accord Fintech

Made with ❤️ in India.

HomeScreens
Login